OncoMark is focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.

Product

OncoMasTR is a novel prognostic test for early stage breast cancer. This gene expression profiling test accurately estimates the risk of recurrence for early-stage breast cancer patients. This test will aid the clinicians in determining the best treatment options for their patients. read more »

Gene expression profiling test for early-stage breast cancer prognosis

Latest News

December 2019: OncoMasTR Clinical Validation Study Published in Peer-Reviewed Journal Clinical Cancer Research

Clinical Cancer Research Published a Key Study on the Clinical Validity of OncoMasTR Conducted by Researchers from The Institute of Cancer Research, Royal Marsden Hospital and Queen Mary University of London.

November 2019: OncoMark Founder Receives Award

OncoMark founder and Chief Scientific Officer Professor William Gallagher has been announced as winner of the prestigious 2019 Science Foundation Ireland (SFI) Entrepreneurship Award at the annual SFI Science Summit held in Athlone.

June 2019: OncoMark to present results from a key study at ASCO 2019

OncoMark to Present Key Study on OncoMasTR Test for Early Stage Breast Cancer at ASCO 2019 in Chicago

Presentation will highlight superior clinical performance of the OncoMasTR test in Irish patients enrolled in the TAILORx Trial

June 2018 - Results of Key Studies Announced

OncoMark Announces Results of Key Studies on Clinical Performance of Prognostic Test for Early Stage Breast Cancer

OncoMark Ltd, an Irish diagnostics company, today announced the results of two key studies on the clinical performance of its OncoMasTR test.